JP2021504317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504317A5 JP2021504317A5 JP2020527927A JP2020527927A JP2021504317A5 JP 2021504317 A5 JP2021504317 A5 JP 2021504317A5 JP 2020527927 A JP2020527927 A JP 2020527927A JP 2020527927 A JP2020527927 A JP 2020527927A JP 2021504317 A5 JP2021504317 A5 JP 2021504317A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituent
- groups
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 150
- 125000001424 substituent group Chemical group 0.000 claims 91
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 75
- 125000005843 halogen group Chemical group 0.000 claims 45
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 44
- 125000000753 cycloalkyl group Chemical group 0.000 claims 44
- 125000003277 amino group Chemical group 0.000 claims 40
- 125000004093 cyano group Chemical group *C#N 0.000 claims 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 34
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 25
- 125000004429 atom Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 102100027159 Membrane primary amine oxidase Human genes 0.000 claims 8
- 101710132836 Membrane primary amine oxidase Proteins 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711163324.7 | 2017-11-21 | ||
| CN201711163324 | 2017-11-21 | ||
| CN201810081619.8 | 2018-01-29 | ||
| CN201810081619 | 2018-01-29 | ||
| CN201810854213.9 | 2018-07-30 | ||
| CN201810854213 | 2018-07-30 | ||
| PCT/CN2018/116606 WO2019101086A1 (zh) | 2017-11-21 | 2018-11-21 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504317A JP2021504317A (ja) | 2021-02-15 |
| JP2021504317A5 true JP2021504317A5 (enExample) | 2021-06-10 |
| JP7305196B2 JP7305196B2 (ja) | 2023-07-10 |
Family
ID=66601549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527927A Active JP7305196B2 (ja) | 2017-11-21 | 2018-11-21 | ハロアリルアミン類のｓｓａｏ／ｖａｐ－１阻害剤とその用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11649233B2 (enExample) |
| EP (1) | EP3715341A4 (enExample) |
| JP (1) | JP7305196B2 (enExample) |
| KR (1) | KR20200094168A (enExample) |
| CN (1) | CN109810041B (enExample) |
| AU (1) | AU2018372889A1 (enExample) |
| CA (1) | CA3083020A1 (enExample) |
| TW (1) | TWI721335B (enExample) |
| WO (1) | WO2019101086A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109810041B (zh) | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
| CN109988109B (zh) * | 2017-12-29 | 2020-12-29 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其用途 |
| KR20190110740A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20190110736A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CN110938059A (zh) * | 2018-09-25 | 2020-03-31 | 上海轶诺药业有限公司 | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 |
| CN113164454A (zh) | 2018-09-28 | 2021-07-23 | 奥克塞拉有限公司 | Vap-1的抑制剂 |
| CA3114166A1 (en) | 2018-09-28 | 2020-04-02 | Acucela Inc. | Inhibitors of vap-1 |
| CN112955214B (zh) | 2018-10-29 | 2024-05-07 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| CN112955215B (zh) | 2018-10-29 | 2024-05-17 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| TWI835945B (zh) * | 2018-12-14 | 2024-03-21 | 南韓商柳韓洋行股份有限公司 | 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物 |
| TW202039486A (zh) | 2018-12-14 | 2020-11-01 | 南韓商柳韓洋行股份有限公司 | 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物 |
| SG11202107498VA (en) * | 2019-01-11 | 2021-08-30 | Nanjing Transthera Biosciences Co Ltd | Haloallylamine compounds and application thereof |
| AU2020377093B2 (en) | 2019-10-29 | 2026-02-26 | Eccogene Inc. | SSAO inhibitors and use thereof |
| CN112876419A (zh) * | 2019-11-29 | 2021-06-01 | 四川科伦博泰生物医药股份有限公司 | 烯丙胺衍生物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1313718A2 (en) * | 2000-07-05 | 2003-05-28 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
| CN1863763A (zh) * | 2003-08-08 | 2006-11-15 | 拉卓拉药物公司 | 用于治疗疾病的氨基脲敏感性胺氧化酶(ssao)和vap－1介导的粘着的抑制剂 |
| CN1921841A (zh) * | 2004-02-25 | 2007-02-28 | 拉卓拉药物公司 | 用于治疗疾病的胺和酰胺类化合物 |
| CA2556914A1 (en) * | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
| EP2004166A2 (en) * | 2006-03-31 | 2008-12-24 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| JP2011504485A (ja) * | 2007-11-21 | 2011-02-10 | ファーマクシス リミテッド | Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途 |
| PT2844637T (pt) | 2012-05-02 | 2018-04-17 | Boehringer Ingelheim Int | Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| EP3617186A1 (en) * | 2017-04-28 | 2020-03-04 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Fluoroallylamine derivative and use thereof |
| CN109251166B (zh) * | 2017-07-13 | 2021-11-05 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| CN110914234B (zh) * | 2017-08-04 | 2023-06-23 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| CN109810041B (zh) | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
| CN109988106B (zh) * | 2017-12-29 | 2023-03-31 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| CN109988093B (zh) * | 2017-12-29 | 2023-04-07 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
-
2018
- 2018-11-20 CN CN201811386564.8A patent/CN109810041B/zh active Active
- 2018-11-21 US US15/733,125 patent/US11649233B2/en active Active
- 2018-11-21 JP JP2020527927A patent/JP7305196B2/ja active Active
- 2018-11-21 TW TW107141484A patent/TWI721335B/zh not_active IP Right Cessation
- 2018-11-21 EP EP18881966.8A patent/EP3715341A4/en not_active Withdrawn
- 2018-11-21 WO PCT/CN2018/116606 patent/WO2019101086A1/zh not_active Ceased
- 2018-11-21 CA CA3083020A patent/CA3083020A1/en active Pending
- 2018-11-21 AU AU2018372889A patent/AU2018372889A1/en not_active Abandoned
- 2018-11-21 KR KR1020207017780A patent/KR20200094168A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504317A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| PH12020551616A1 (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| JP2019504050A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| JP2015531366A5 (enExample) | ||
| IL313466B1 (en) | Inhibiting creb binding protein (cbp) | |
| RU2015149009A (ru) | 19-нор нейроактивные стероиды и способы их применения | |
| JP2016503052A5 (enExample) | ||
| HRP20201916T1 (hr) | Trifluorometil supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi | |
| RU2015127827A (ru) | Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков | |
| JP2016505637A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| JP2016531871A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
| JP2018507166A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| GEAP201914608A (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors |